Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guided by Light: Real-time Fluorescence Imaging for Oral Cancer Surgery
2019-003416-30Phase 2Active
- Sponsor
- Erasmus MC
- Start
- Dec 2020
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cRGD-ZW800-1 in Oral Mucosal Carcinoma, sponsored by Erasmus MC. Primary endpoint: Rate of adequate tumor resection margins. Started Dec 2020; status: active.
02
Drugs
cRGD-ZW800-1
03
Conditions
Oral Mucosal Carcinoma
Beyond the preview
Go deeper on 2019-003416-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003416-30.